news
UK Government launches Pandemic Preparedness Partnership group
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
List view / Grid view
Vaccine
news
DNA vaccine protects non-human primates against MERS, study shows
A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
news
Novel COVID-19 vaccine could offer broad protection from coronaviruses
A new COVID-19 vaccine could provide protection from severe infection from a range of coronaviruses, studies in pigs have shown.
news
Spikes from AstraZeneca COVID-19 vaccine resemble SARS-CoV-2 S proteins
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
news
Dynamic model of SARS-CoV-2 S protein reveals vaccine targets
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
news
Novel Zika virus vaccine shows success in pre-clinical trials
A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
news
Tumour cell vaccine strategy developed for neuroblastoma and melanoma
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
article
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
article
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
article
Drug Target Review Vaccine Development ebook 2021
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
article
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
article
COVID-19 in Europe – one year on from the first case
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
news
Nanoparticle vaccine shown to block range of flu strains in pre-clinical study
A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
article
Drug Target Review – Issue 1 2021
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
